Abstract
Osimertinib and thoracic radiotherapy (TRT) are established therapies for epidermal growth factor receptor mutated (EGFR+) metastatic non-small cell lung cancer (mNSCLC). However, pneumonitis is a known side effect independently associated with both treatment modalities. The objective of this study was to examine the impact of concurrent Osimertinib and TRT on the incidence of pneumonitis, and to observe patterns of practice regarding the cessation of Osimertinib during TRT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
